These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

79 related articles for article (PubMed ID: 9272317)

  • 1. Fluoroquinolone therapy in pediatrics: where we stand.
    Sabella C; Goldfarb J
    Clin Pediatr (Phila); 1997 Aug; 36(8):445-8. PubMed ID: 9272317
    [No Abstract]   [Full Text] [Related]  

  • 2. Fluoroquinolone pharmacodynamics: prospective determination of relationships between exposure and outcome.
    Drusano GL
    J Chemother; 2000 Oct; 12 Suppl 4():21-6. PubMed ID: 11131956
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Quinolone antimicrobial agents.
    Neu HC
    Annu Rev Med; 1992; 43():465-86. PubMed ID: 1580602
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Multiple combination bactericidal antibiotic testing for patients with cystic fibrosis infected with multiresistant strains of Pseudomonas aeruginosa.
    Lang BJ; Aaron SD; Ferris W; Hebert PC; MacDonald NE
    Am J Respir Crit Care Med; 2000 Dec; 162(6):2241-5. PubMed ID: 11112146
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Impact of fluoroquinolone administration on the emergence of fluoroquinolone-resistant gram-negative bacilli from gastrointestinal flora.
    Richard P; Delangle MH; Raffi F; Espaze E; Richet H
    Clin Infect Dis; 2001 Jan; 32(1):162-6. PubMed ID: 11112677
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Efficacy and future of the aerosoltherapy in the treatment of cystic fibrosis patients infected by Pseudomonas aeruginosa].
    Rognon A; Curti C; Montana M; Terme T; Rathelot P; Vanelle P
    Therapie; 2011; 66(6):481-91. PubMed ID: 22186073
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Resistance to ciprofloxacin of respiratory pathogens in patients with cystic fibrosis.
    Hurley JC; Grimwood K; Williams T
    Med J Aust; 1992 May; 156(9):662-3. PubMed ID: 1625625
    [No Abstract]   [Full Text] [Related]  

  • 8. Post-antibiotic effect of colistin, alone and in combination with amikacin, on Pseudomonas aeruginosa strains isolated from cystic fibrosis patients.
    Bozkurt-Güzel C; Gerçeker AA
    J Antibiot (Tokyo); 2012 Feb; 65(2):83-6. PubMed ID: 22126897
    [No Abstract]   [Full Text] [Related]  

  • 9. Suboptimal ciprofloxacin dosing as a potential cause of decreased Pseudomonas aeruginosa susceptibility in children with cystic fibrosis.
    Guillot E; Sermet I; Ferroni A; Chhun S; Pons G; Zahar JR; Jullien V
    Pharmacotherapy; 2010 Dec; 30(12):1252-8. PubMed ID: 21114393
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical application of direct sputum sensitivity testing in a severe infective exacerbation of cystic fibrosis.
    Serisier DJ; Jones G; Tuck A; Connett G; Carroll MP
    Pediatr Pulmonol; 2003 Jun; 35(6):463-6. PubMed ID: 12746944
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Mechanisms of resistance in Pseudomonas aeruginosa].
    Cercenado Mansilla E; García Garrote F
    Rev Clin Esp; 1998 Sep; 198 Suppl 2():10-6. PubMed ID: 9844472
    [No Abstract]   [Full Text] [Related]  

  • 12. [The pharmacokinetics of fluoroquinolones in different diseases].
    Iakovlev VP; Izotova GN; Iakovlev SV
    Antibiot Khimioter; 1997; 42(1):23-9. PubMed ID: 9221701
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The use of fluoroquinolones in children.
    Leibovitz E
    Curr Opin Pediatr; 2006 Feb; 18(1):64-70. PubMed ID: 16470165
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Avoiding fluoroquinolone resistance. Strategies for primary care practice.
    Stratton CW
    Postgrad Med; 1997 Mar; 101(3):247-50, 255. PubMed ID: 9074562
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Selective oral decontamination in cystic fibrosis: an attempt to prevent pseudomonas colonisation.
    Dalzell AM; van Saene HK; Heaf DP
    Acta Univ Carol Med (Praha); 1990; 36(1-4):40-1. PubMed ID: 2130715
    [No Abstract]   [Full Text] [Related]  

  • 16. [Pseudomonas infection in mucoviscidosis. Therapeutic strategies].
    Foucaud P; Bingen E; Lambert-Zechovsky N; Navarro J
    Presse Med; 1990 May; 19(21):983-5. PubMed ID: 2141150
    [No Abstract]   [Full Text] [Related]  

  • 17. Antibacterial activity of fluoroquinolones in combination with zidovudine.
    Lewin CS; Allen RA; Amyes SG
    J Med Microbiol; 1990 Oct; 33(2):127-31. PubMed ID: 2121991
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Relationship between fluoroquinolone area under the curve: minimum inhibitory concentration ratio and the probability of eradication of the infecting pathogen, in patients with nosocomial pneumonia.
    Drusano GL; Preston SL; Fowler C; Corrado M; Weisinger B; Kahn J
    J Infect Dis; 2004 May; 189(9):1590-7. PubMed ID: 15116294
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pulmonary exacerbations in cystic fibrosis: it's time to be explicit!
    Marshall BC
    Am J Respir Crit Care Med; 2004 Apr; 169(7):781-2. PubMed ID: 15044219
    [No Abstract]   [Full Text] [Related]  

  • 20. Relationship between fluoroquinolone use and changes in susceptibility to fluoroquinolones of selected pathogens in 10 United States teaching hospitals, 1991-2000.
    Zervos MJ; Hershberger E; Nicolau DP; Ritchie DJ; Blackner LK; Coyle EA; Donnelly AJ; Eckel SF; Eng RH; Hiltz A; Kuyumjian AG; Krebs W; McDaniel A; Hogan P; Lubowski TJ
    Clin Infect Dis; 2003 Dec; 37(12):1643-8. PubMed ID: 14689346
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.